Suppr超能文献

相似文献

1
Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.
Haematologica. 2010 Jul;95(7):1090-7. doi: 10.3324/haematol.2009.014407. Epub 2010 Feb 4.
2
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.
3
Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.
6
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23.
7
[Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Korean J Lab Med. 2009 Jun;29(3):243-8. doi: 10.3343/kjlm.2009.29.3.243.
10
Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Clin Chem Lab Med. 2015 Jun;53(7):1005-11. doi: 10.1515/cclm-2014-0858.

引用本文的文献

1
Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms.
Cancers (Basel). 2025 May 30;17(11):1834. doi: 10.3390/cancers17111834.
3
Topics of Interest in Women With Myeloproliferative Neoplasms.
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):74-87. doi: 10.1002/ajh.27665. Epub 2025 Mar 14.
4
Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients.
Asian Pac J Cancer Prev. 2025 Feb 1;26(2):677-684. doi: 10.31557/APJCP.2025.26.2.677.
5
Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.
Ann Hematol. 2024 Sep;103(9):3543-3551. doi: 10.1007/s00277-024-05894-7. Epub 2024 Jul 24.
6
Blood cell JAKtivation aggravates cerebral venous thrombosis.
Blood Adv. 2024 Jun 25;8(12):3327-3329. doi: 10.1182/bloodadvances.2024012977.
7
Interferons in the treatment of myeloproliferative neoplasms.
Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024.
8
The mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden.
EJHaem. 2023 Oct 31;4(4):1071-1080. doi: 10.1002/jha2.805. eCollection 2023 Nov.
10
JAK2 V617F allele burden in polycythemia vera: burden of proof.
Blood. 2023 Apr 20;141(16):1934-1942. doi: 10.1182/blood.2022017697.

本文引用的文献

1
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Hematology. 2009 Feb;14(1):11-5. doi: 10.1179/102453309X385188.
3
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.
4
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22.
5
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
Blood. 2008 Apr 15;111(8):3931-40. doi: 10.1182/blood-2007-08-107748. Epub 2007 Dec 26.
6
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23.
7
8
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Cancer. 2007 Jun 1;109(11):2279-84. doi: 10.1002/cncr.22663.
10
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.
Blood. 2006 Dec 1;108(12):3913-5. doi: 10.1182/blood-2006-03-008805. Epub 2006 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验